WO2015006999A1 - Lacrimal ductile blocking core - Google Patents

Abstract

A lacrimal ductile blocking core comprises a blocking core tube body (1). One end of the blocking core tube body (1) is provided with a taper-shaped tip (3), and the other end thereof is provided with a blocking core head end (2). The lacrimal ductile blocking core not only can be used for treating xerophthalmia conveniently and safely, but also can prevent lacrimal passages from becoming narrow after acid and alkali burns, and the blocking core head end (2) can be taken out or planted into the lacrimal passages conveniently by tweezers.

Description

 Tear tube

Technical field

The invention relates to the technical field of medical instruments, in particular to a lacrimal canal core for treating dry eye and preventing narrowing of lacrimal passage after acid-base burn.

Background technique

Dry eye syndrome refers to symptoms such as decreased tears or decreased function of lacrimal glands causing dry eyes, acid eyes, itchy eyes, photophobia, and decreased vision. It damages the cornea and, in severe cases, corneal softening and perforation.

The current important method for treating dry eye syndrome is puncture embolization. The method is to seal the tear exclusion tube by implanting a lacrimal duct embolization. The method preserves the natural tears secreted by the lacrimal passage itself and prolongs the time the tears stay on the surface of the eye. However, due to insufficient length of the lacrimal plug, neither degradable nor permanent lacrimal plugs can treat dry eye.

In addition, the lacrimal passage formed after acid-base burns is narrowed, and there is no mature treatment and prevention means at present.

Summary of the invention

Based on this, the present invention overcomes the defects of the prior art and provides a lacrimal tube obstruction core, which can not only treat dry eye disease conveniently, safely and stably, but also prevent narrowing of the lacrimal passage after acid-base burn.

The technical solution is as follows: a tear tube small core, comprising a core tube, the core tube has a tapered tip at one end, and the other end of the core tube has a core end.

Preferably, the head end of the core block has a flat cylindrical shape without an angular shape, and the head end has no angular angle, and the degree of damage to the eye tissue is low.

Preferably, the core tube body has a length of 2-20 mm, the diameter of the core tube body is 0.1 to 1 mm, the thickness of the core end of the resistor core is 0.1 to 1 mm, and the diameter of the head end of the resistor core is 0.5 to 1.5 mm. It is suitable for the treatment of lacrimal passages of different patients, and the core tube is long enough. After entering the lacrimal duct, the shape can be deformed with the curvature of the lacrimal duct. Therefore, the tear tube has a strong contact with the lacrimal duct, and thus does not slip into tears. The road is also not easy to blink and fall out, and the position is fixed for a long time.

Preferably, the core tube has a length of 4 to 16 mm, the diameter of the core tube is 0.3 to 0.8 mm, the thickness of the core end of the core is 0.3 to 0.8 mm, and the diameter of the head end of the core is 0.7 to 1.0 mm.

Preferably, the core tube body and the core end of the core are processed by a medical silica gel material or processed by a polyolefin or a polyester medical polymer material, and the material is non-sticky to the nascent cells and can maintain the lacrimal passage. The shape enters, therefore, the proliferating tissue cells after acid-base burn do not adhere to the lacrimal tube and prevent the narrowing of the lacrimal duct. Secondly, the tear-throat block of the material can adsorb drugs and nutritional factors, drugs and Nutritional factors can be applied to the surface of the lacrimal canal, so the effect of treating dry eye is particularly significant.

Preferably, the core tube is provided with a cavity, a micro hole is arranged in the core tube body, and a drug or a nutrient factor is placed in the cavity, and the micro hole can be slowly released and then used by the eye. Absorption, can better treat eye acid and alkali burn symptoms and dry eye syndrome.

Preferably, the tapered tip has a hollow structure, the head of the tapered tip is blunt and has an opening, and the core tube body and the head end of the resistance core have a hollow structure, and the tear tube is blocked. Core implantation, the hollow tube of the tear duct adopts a hollow structure in order to allow excess tear fluid to flow out of the eye through the hollow structure of the tear duct and prevent the tears in the lacrimal duct from being moderate.

The principle, effect and the like of the foregoing technical solutions are described below: when the tear canal of the structure is implanted into the lacrimal duct, the dry eye can be treated conveniently, safely and stably, and the tears after the acid-base burn can be prevented. The channel is narrowed and, because of its head end, it can be easily removed or implanted into the lacrimal passage by the forceps.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic structural view of a tear canal core of the present invention;
Figure 2 is a side view of Figure 1;
3 is a schematic structural view of a tear tube small core according to Embodiment 1 of the present invention;
4 is a schematic structural view of a tear canal core of the second embodiment of the present invention.

Description of the reference signs:
1, the core tube body, 2, the core end, 3, tapered tip, 4, micro-hole, 5, cavity.

detailed description

The embodiments of the present invention are described in detail below.

As shown in FIG. 1 and FIG. 2, a lacrimal canal core comprises a core preventing tube body 1 having a tapered tip 3 at one end, and the other end of the core preventing tube body 1 has a core preventing head. End 2. The head end 2 of the core block has a flat cylindrical shape without an angular shape, and the end portion 2 of the core block has no angular shape, and the degree of damage to the eye tissue cells is low. When the tear canal of the structure is implanted into the lacrimal duct, the dry eye can be treated conveniently, safely and stably, and the lacrimal passage can be prevented from narrowing after the acid-base burn, and since it has a head end, it can be conveniently The tweezers are removed or implanted into the lacrimal passage. Since the core tube 1 is long enough to be deformed after the lacrimal passage is implanted, the shape of the lacrimal tube is deformed by the curvature of the lacrimal duct, so that the lacrimal tube is in firm contact with the lacrimal passage, and thus does not slide down to the lacrimal passage, and is not easily blinked. Out, the position is fixed for a long time. According to the length of the lacrimal passage of different people, the size of the tear tube is suitable for treating different patients:
The core tube body 1 has a length of 2 mm, the core tube body 1 has a diameter of 0.1 mm, the core end portion 2 has a thickness of 0.1 mm, and the core end portion 2 has a diameter of 0.5 mm. A patient with dry eye syndrome recovers 28 days after using a tear tube of this size every day.
The core tube body 1 has a length of 4 mm, the core tube body 1 has a diameter of 0.3 mm, the core end portion 2 has a thickness of 0.3 mm, and the core end portion 2 has a diameter of 0.7 mm. Patients with dry eye syndrome B recovered 33 days after using the tear tube of this size every day.
The core tube body 1 has a length of 8 mm, the core tube body 1 has a diameter of 0.5 mm, the core end portion 2 has a thickness of 0.5 mm, and the core end portion 2 has a diameter of 0.9 mm. Patients with dry eye syndrome were rehabilitated 32 days after using a small size of this class of tear ducts.
The core tube body 1 has a length of 10 mm, the core tube body 1 has a diameter of 0.8 mm, the core end portion 2 has a thickness of 0.8 mm, and the core end portion 2 has a diameter of 1.2 mm. In patients with dry eye syndrome, the patient is rehabilitated for 36 days after using the tear tube of this size every day. The patient who is burned by acid and alkali burns the core of the tear tube with this size every day. The preventive effect is good and the lacrimal duct is not narrowed. , 96 days of rehabilitation.
The core tube body 1 has a length of 16 mm, the core tube body 1 has a diameter of 0.9 mm, the core end portion 2 has a thickness of 0.9 mm, and the core end portion 2 has a diameter of 1.3 mm. Patients with dry eye syndrome have used this type of tear tube to prevent core, and recovered for 40 days. Patients with acid-base burns use the tear tube of this size every day. The preventive effect is good and the lacrimal duct is not narrowed. , 98 days of recovery.
The core tube body 1 has a length of 20 mm, the core tube body 1 has a diameter of 1 mm, the core end portion 2 has a thickness of 1 mm, and the core end portion 2 has a diameter of 1.5 mm. Patients with dry eye syndrome use 37-day rehabilitated tears of the small size of the tear tube after daily use. Patients with acid-base burns use the tear ducts of this size every day. The preventive effect is good and the lacrimal passage is not narrowed. , 100 days of recovery.

After testing and analysis, it can be seen that when the length of the core tube is 2-8 mm, it is effective as a treatment for dry eye, and is not suitable for preventing narrowing of the lacrimal passage after acid-base burn. When the length of the core tube is 8-20 mm, it can be used to treat dry eye and prevent narrowing of the lacrimal passage after acid-base burn.

Wherein, the core tube body 1 and the core end 2 of the invention are processed by a medical silica gel material or processed by a polyolefin or a polyester medical polymer material, and the material is non-sticky to the new cells, Maintaining the shape of the lacrimal duct, therefore, the proliferating tissue cells after acid-base burn do not adhere to the lacrimal tube and prevent the narrowing of the lacrimal duct. Secondly, the tear-tube-resistance of the material can adsorb drugs and nutritional factors. Drugs and trophic factors can be applied to the surface of the lacrimal canal, so the effect of treating dry eye is particularly significant.

Embodiment 1, as shown in FIG. 3, the core tube body 1 is provided with a cavity 5, and the core tube body 1 is provided with a micro hole 4 through the core end 2 to the cavity 5 Injecting drugs or nutrient factors, etc., drugs or nutrient factors are slowly absorbed into the lacrimal passage through the micropores 4 and absorbed by the eyes, which can better treat the symptoms of acid-base burns and dry eye in the eyes.

Embodiment 2, as shown in FIG. 4, the tapered tip 3 has a hollow structure, the head of the tapered tip 3 is blunt and has an opening, and the core tube body 1 and the core end 2 They all have a hollow structure, and the tear canal is prevented from being inserted into the core. The hollow structure of the tear tube is designed to allow excess tears to flow out of the eye through the hollow structure of the tear canal, keeping the tears in the eye moderate and treating dry eyes. The effect of the disease is significant.

The above-mentioned embodiments are merely illustrative of specific embodiments of the invention, and the description thereof is not to be construed as limiting the scope of the invention. It should be noted that a number of variations and modifications may be made by those skilled in the art without departing from the spirit and scope of the invention.

Claims (7)

 A tear tube small-barrier core, comprising: a core-blocking tube body having a tapered tip at one end and a core-blocking end at the other end of the core-blocking tube body. The lacrimal canal core according to claim 1, wherein the end of the core block has a flat cylindrical shape without an angular shape. The lacrimal canal core according to claim 1, wherein the core tube has a length of 2 to 20 mm, the core tube has a diameter of 0.1 to 1 mm, and the core end has a thickness of 0.1 to 1 mm. The diameter of the head end is 0.5 to 1.5 mm. The lacrimal canal core according to claim 3, wherein the core tube has a length of 4 to 16 mm, the core tube has a diameter of 0.3 to 0.8 mm, and the core end has a thickness of 0.3 to 0.8 mm. The diameter of the tip end of the core is 0.7 to 1.2 mm. The lacrimal canal core according to claim 1, wherein the core tube body and the core end of the core are processed by a medical silica gel material or processed by a polyolefin or a polyester medical polymer material. The lacrimal canal core according to claim 1 or 5, wherein the core tube is provided with a cavity, and the core tube is provided with micropores. The punctal canal core according to claim 1 or 5, wherein the tapered tip has a hollow structure, the head of the tapered tip is blunt and has an opening, and the core tube body is The head ends of the core are hollow.

Images